A Phase 2 interventional study of BMS-986278 Placebo and BMS-986278 in Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb. Completed at 119 sites in 18 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 10th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2020, is one of 43 in phase 2, and was the 81st registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
PureTech · Sites in United States, Canada
Ages 40+
Peter Caravan · Sites in United States
Ages 18–80
University of Wisconsin, Madison · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 48 · Phase 3 17 · Phase 4 3
First in 1978; this study’s year is marked. 9 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 403 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 50 across the 90 interventional studies, 200 across the 37 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 128 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 9 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT00515567University of ChicagoExplanted Lung Tissues With Pulmonary Fibrosis | 2026-12 |
| NCT06567717Cedars-Sinai Medical CenterZinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis | 2027-01 |
| NCT04964115Vanderbilt University Medical CenterPost Acute Sequelae of COVID-19 | 2027-05-31 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the idiopathic pulmonary fibrosis (IPF) Cohort
For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
Drug: BMS-986278
Drug: BMS-986278
Other: BMS-986278 Placebo
PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
Drug: BMS-986278
Drug: BMS-986278
Other: BMS-986278 Placebo
Specified Dose on Specified Days
Specified Dose on Specified Days
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants
Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for the IPF cohort only as pre-specified in the protocol.
Time frame: From baseline (first dose) up to week 26
The Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose up to 30 days after last dose during the main study treatment phase
The Number of Participants Experiencing Serious Adverse Events (SAEs)
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose up to 30 days after last dose during the main study treatment phase
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
The number of participants who discontinued study treatment due to adverse events (AEs)
Time frame: From first dose up to 30 days after last dose during the main study treatment phase
The Number of Participants Who Died Due to Adverse Events (AEs)
The number of participants who died while receiving study treatment due to an adverse event
Time frame: From first dose up to 30 days after last dose during the main study treatment phase
Maximum Concentration (Cmax)
Cmax is defined as the maximum concentration of the analyte recorded in the participants. Cmax of BMS-986278 and BMT-327319 was derived from plasma concentration versus time data.
Time frame: On Day 1 and Week 4 (Day 29)
Time to Maximum Concentration (Tmax)
Tmax is defined as the amount of time until the maximum concentration of the analyte is recorded in the participants
Time frame: On Day 1 and Week 4 (Day 29)
Area Under Curve (AUC0-8)
Area under the plasma concentration-time curve (AUC) from the timepoint of 0 hours to 24 hours post dose as measured on Day 1 and Week 4.
Time frame: On Day 1 and Week 4 (Day 29)
Concentration Trough (Ctrough)
Ctrough is defined as the lowerst concentration of drug in the blood immediately before the next dose is administered
Time frame: On Week 4 (Day 29) and Week 12 (Day 85)
The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities
A frequency summary of investigator clinical interpretation of ECG abnormal findings is listed.
Time frame: At Week 26
Change From Baseline in Vital Sign Measurements
The change from baseline in select vital sign measurements. Baseline is defined as first dose.
Time frame: At baseline and Week 26
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants
Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for PF-ILD cohort only as pre-specified in the protocol.
Time frame: At baseline and Week 26
The Number of Participants With ≥ 10% Absolute Decline in ppFVC (%)
The number of participants with ≥ 10% absolute decline in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant. The number of participants represented signify the number of participants with applicable data during the specific visit at the specific timepoint.
Time frame: At Weeks 4, 8, 12, 16, 20, and 26
The Number of Participants With 0% Change in ppFVC (%)
The number of participants with 0% change in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
Time frame: Weeks 4, 8, 12, 16, 20, and 26
Time to First Occurrence ≥ 10% Absolute Decline in ppFVC (%)
The amount of time in weeks to the participant's first occurrence ≥ 10% absolute decline in Percent Predicted Forced Vital Capacity (ppFVC). A participant's time is censored at the last observed time prior to discontinuation if a participant discontinues study without event, or at week 26 if a participant does not experience the event until the end of week 26. Kaplan-Meier product limit method will be employed to estimate the survival curves. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
Time frame: From first dose up to the first occurrence of ≥ 10% absolute decline in ppFVC
Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC)
The absolute change in ppFVC (%) is measured from baseline up to the pre-specified timepoints of Weeks 4, 8, 12, 16, 20, and 26. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air (mL) exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
Time frame: From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Absolute Change From Baseline in Forced Vital Capacity (FVC)
Forced vital capacity (FVC) is defined as the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. The absolute change in FVC (mL) is measured from baseline up to Weeks 4, 8, 12, 16, 20, and 26.
Time frame: From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)
The absolute change in single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.
Time frame: From baseline up to Week 26
Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)
The absolute change in percent predicted single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.
Time frame: From baseline up to Week 26
Absolute Change From Baseline in Walking Endurance/Distance
The absolute change in walking endurance/distance as determined by the 6-minute walk test (6MWT) from baseline to Week 26. The 6-Minute Walk Test (6MWT) is a submaximal exercise test used to assess aerobic capacity and endurance. Baseline is defined as first dose.
Time frame: From baseline up to Week 26
Time to First Acute Exacerbation
Time to first acute exacerbations of lung fibrosis was measured from the day of first dose up to the day of first acute exacerbation. Participants who discontinued the study treatment prior to the end of the main study without experiencing the event were excluded from the analysis. A participant's time was censored at the last observed time prior to discontinuation if a participant discontinued study without event, or at week 26 if a participant did not experience the event until the end of week 26. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload
Time frame: From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first
The Number of Participants Experiencing Acute Exacerbation
The number of participants experiencing acute exacerbations of lung fibrosis. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload
Time frame: From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first
| Milestone | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | IPF Cohort - BMS-986278 10mg | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | PF-ILD Cohort - 10mg BMS-986278 |
|---|---|---|---|---|---|---|---|---|
| Started | 93 | 92 | 93 | 0 | 41 | 42 | 42 | 0 |
| Completed | 92 | 91 | 93 | 0 | 41 | 40 | 42 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Not reported | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 |
| Milestone | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | IPF Cohort - BMS-986278 10mg | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | PF-ILD Cohort - 10mg BMS-986278 |
|---|---|---|---|---|---|---|---|---|
| Started | 92 | 91 | 93 | 0 | 41 | 40 | 42 | 0 |
| Completed | 82 | 82 | 84 | 0 | 33 | 37 | 40 | 0 |
| Not completed | 10 | 9 | 9 | 0 | 8 | 3 | 2 | 0 |
| Withdrew: Withdrawal by participant | 2 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Other reasons | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Participant no longer meets study criteria | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 6 | 5 | 5 | 0 | 6 | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | IPF Cohort - BMS-986278 10mg | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | PF-ILD Cohort - 10mg BMS-986278 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 100 | 102 | 11 | 0 | 41 | 46 | 4 |
| Pbo bms-986278 30 mg | 0 | 33 | 0 | 0 | 0 | 13 | 0 | 0 |
| Pbo bms-986278 60 mg | 0 | 0 | 30 | 0 | 0 | 0 | 14 | 0 |
| Completed | 0 | 96 | 89 | 8 | 0 | 39 | 42 | 4 |
| Not completed | 0 | 4 | 13 | 3 | 0 | 2 | 4 | 0 |
| Withdrew: Withdrawal by participant | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 | 8 | 3 | 0 | 1 | 2 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for the IPF cohort only as pre-specified in the protocol.
| Percent change from baseline in ppFVC | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants | -2.807 ± 0.7286 | -3.068 ± 0.7335 | -1.120 ± 0.6691 | — | — | — |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) | 74 | 69 | 69 | 32 | 33 | 28 |
A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Serious Adverse Events (SAEs) | 16 | 10 | 10 | 13 | 4 | 6 |
The number of participants who discontinued study treatment due to adverse events (AEs)
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 9 | 9 | 6 | 7 | 1 | 0 |
The number of participants who died while receiving study treatment due to an adverse event
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Who Died Due to Adverse Events (AEs) | 2 | 3 | 4 | 3 | 0 | 0 |
Cmax is defined as the maximum concentration of the analyte recorded in the participants. Cmax of BMS-986278 and BMT-327319 was derived from plasma concentration versus time data.
| ng/mL | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Day 1; Analyte: BMS-986278 | — | 465.0 ± 36.23 | 1089.8 ± 42.06 | — | 715.4 ± 2.87 | 1112.3 ± 77.45 |
| Day 1; Analyte: BMT-323719 | — | 114.66 ± 32.147 | 167.35 ± 39.538 | — | 94.8 ± 10.39 | 189.6 ± 86.07 |
| Day 29; Analyte: BMS-986278 | — | 641.0 ± 27.68 | 1301.3 ± 20.80 | — | 691.9 ± 2.04 | 1247.80 ± 29.84 |
| Day 29; Analyte: BMT-323719 | — | 169.30 ± 28.104 | 275.82 ± 34.554 | — | 161.9 ± 30.60 | 433.5 ± 58.73 |
Tmax is defined as the amount of time until the maximum concentration of the analyte is recorded in the participants
| Hours | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Day 1; Analyte: BMS-986278 | — | 2.0170 (1.567 to 4.100) | 1.6670 (1.283 to 5.917) | — | 1.55 (1.50 to 1.60) | 2.01 (1.83 to 2.18) |
| Day 1; Analyte: BMT-323719 | — | 4.0670 (1.867 to 7.900) | 4.0330 (1.900 to 8.000) | — | 7.96 (7.92 to 8.00) | 4.10 (3.98 to 4.22) |
| Day 29; Analyte: BMS-986278 | — | 1.9080 (1.450 to 4.117) | 1.6750 (1.317 to 4.000) | — | 2.68 (1.533 to 3.82) | 4.06 (3.98 to 4.13) |
| Day 29; Analyte: BMT-323719 | — | 4.0670 (2.083 to 6.000) | 2.0085 (1.417 to 7.850) | — | 5.79 (4.10 to 7.48) | 3.74 (1.48 to 6.00) |
Area under the plasma concentration-time curve (AUC) from the timepoint of 0 hours to 24 hours post dose as measured on Day 1 and Week 4.
| h*ng/mL | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Day 1; Analyte: BMS-986278 | — | 1990.4530 ± 20.78185 | 4430.5891 ± 31.16188 | — | 3358 ± 8.7 | 4347 ± 61.3 |
| Day 1; Analyte: BMT-323719 | — | 686.2045 ± 32.95587 | 913.4300 ± 50.72949 | — | 532 ± NA | 2081 ± NA |
| Day 29; Analyte: BMS-986278 | — | 2853.9081 ± 21.72108 | 5433.1662 ± 25.62819 | — | 3591 ± NA | 8107 ± NA |
| Day 29; Analyte: BMT-323719 | — | 1179.6486 ± 31.27987 | 1784.7369 ± 30.32795 | — | — | 2839 ± 45.8 |
Ctrough is defined as the lowerst concentration of drug in the blood immediately before the next dose is administered
| ng/mL | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Day 29-BMS-986278 | — | 92.1 (13.5 to 433) | 217 (32.4 to 1540) | — | 116.0000 (26.300 to 392.000) | 286.0000 (49.600 to 2659.000) |
| Day 85-BMS-986278 | — | 84.2 (16.7 to 389) | 199 (5.37 to 726) | — | 88.7000 (20.100 to 380.000) | 196.0000 (68.000 to 1773.000) |
| Day 29-BMT-323719 | — | 60.3 (12.9 to 207) | 141 (52.4 to 384) | — | 75.5000 (0.200 to 121.000) | 177.5000 (0.200 to 693.000) |
| Day 85-BMT-323719 | — | 64.2 (0.200 to 174) | 132 (0.200 to 371) | — | 67.4500 (11.000 to 186.000) | 156.0000 (0.200 to 326.000) |
A frequency summary of investigator clinical interpretation of ECG abnormal findings is listed.
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities | 27 | 18 | 31 | 5 | 9 | 12 |
The change from baseline in select vital sign measurements. Baseline is defined as first dose.
| Change from baseline in mmHg | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Sitting Diastolic Blood Pressure - 0 Hours Pre-Dose | 0.0 (-20 to 19) | 0.0 (-21 to 20) | 1.0 (-16 to 24) | 3.0 (-9 to 13) | 1.0 (-18 to 17) | -1.0 (-27 to 15) |
| Standing Diastolic Blood Pressure - 0 Hours Pre-Dose | -2.0 (-18 to 15) | 0.0 (-28 to 22) | 1.0 (-24 to 30) | 1.5 (-15 to 26) | -0.5 (-14 to 20) | 0.0 (-18 to 16) |
| Supine Diastolic Blood Pressure - 0 Hours Pre-Dose | -1.0 (-12 to 18) | 1.0 (-25 to 17) | 1.0 (-23 to 19) | 2.5 (-13 to 15) | 0.0 (-8 to 17) | 0.0 (-14 to 14) |
| Sitting Systolic Blood Pressure - 0 Hours Pre-Dose | -1.0 (-29 to 37) | 1.0 (-23 to 30) | 3.0 (-22 to 34) | 0.0 (-35 to 17) | 1.0 (-22 to 37) | -1.0 (-49 to 34) |
| Standing Systolic Blood Pressure - 0 Hours Pre-Dose | -3.0 (-27 to 28) | -1.5 (-35 to 31) | 3.0 (-28 to 36) | 0.5 (-38 to 33) | 0.5 (-23 to 28) | 0.0 (-34 to 26) |
| Supine Systolic Blood Pressure - 0 Hours Pre-Dose | 0.0 (-24 to 34) | 0.0 (-25 to 43) | 3.0 (-24 to 24) | 2.5 (-29 to 25) | 2.0 (-20 to 49) | -3.0 (-30 to 23) |
Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtracting the baseline value from the new value, dividing by the baseline value, and then multiplying by 100%. The percent change in this endpoint was calculated from ppFVC values taken at baseline, which is defined as the measurement of ppFVC taken at first dose, and ppFVC values taken at Week 26. This endpoint reports data for PF-ILD cohort only as pre-specified in the protocol.
| Percent change from baseline | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants | — | — | — | -2.681 ± 1.4730 | 2.717 ± 0.9054 | -1.203 ± 0.8808 |
The number of participants with ≥ 10% absolute decline in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant. The number of participants represented signify the number of participants with applicable data during the specific visit at the specific timepoint.
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Week 4 | 3 | 0 | 2 | 0 | 0 | 0 |
| Week 8 | 4 | 4 | 3 | 2 | 0 | 0 |
| Week 12 | 4 | 1 | 3 | 1 | 0 | 0 |
| Week 16 | 3 | 2 | 2 | 2 | 0 | 0 |
| Week 20 | 10 | 1 | 1 | 2 | 1 | 0 |
| Week 26 | 7 | 7 | 4 | 3 | 3 | 1 |
The number of participants with 0% change in percent predicted forced vital capacity (ppFVC) at pre-specified timepoints. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Week 4 | 48 | 41 | 33 | 14 | 12 | 13 |
| Week 8 | 47 | 43 | 69 | 15 | 13 | 12 |
| Week 12 | 46 | 43 | 39 | 17 | 13 | 13 |
| Week 16 | 51 | 45 | 39 | 15 | 11 | 18 |
| Week 20 | 51 | 40 | 33 | 18 | 15 | 18 |
| Week 26 | 53 | 42 | 34 | 17 | 22 | 19 |
The amount of time in weeks to the participant's first occurrence ≥ 10% absolute decline in Percent Predicted Forced Vital Capacity (ppFVC). A participant's time is censored at the last observed time prior to discontinuation if a participant discontinues study without event, or at week 26 if a participant does not experience the event until the end of week 26. Kaplan-Meier product limit method will be employed to estimate the survival curves. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
| Weeks | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Time to First Occurrence ≥ 10% Absolute Decline in ppFVC (%) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (26.3 to NA) | NA (NA to NA) |
The absolute change in ppFVC (%) is measured from baseline up to the pre-specified timepoints of Weeks 4, 8, 12, 16, 20, and 26. ppFVC is the maximum capacity of air that a participant can exhale after a maximum inspiration. It measures the volume of air (mL) exhaled in a spirometer, after a maximal inspiration. It is reported as the percentage of the predicted value for the participant.
| Percentage of predicted value | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Absolute change from Baseline to Week 4 | -1.491 ± 4.3773 | -0.482 ± 4.2499 | 0.023 ± 5.4007 | 1.119 ± 6.0123 | 0.327 ± 3.1862 | 0.217 ± 3.5946 |
| Absolute change from Baseline to Week 8 | -1.783 ± 4.5234 | -1.046 ± 4.8192 | -1.079 ± 5.1294 | -0.334 ± 7.6326 | 0.966 ± 3.2631 | 0.475 ± 3.2802 |
| Absolute change from Baseline to Week 12 | -1.974 ± 5.0324 | -0.589 ± 4.8575 | -1.109 ± 5.9152 | -2.012 ± 5.5436 | 0.114 ± 4.2490 | 0.196 ± 3.7168 |
| Absolute change from Baseline to Week 16 | -2.422 ± 5.0040 | -1.042 ± 5.1644 | -1.220 ± 4.3475 | -1.180 ± 7.6897 | -0.197 ± 4.5490 | -0.394 ± 4.3439 |
| Absolute change from Baseline to Week 20 | -2.625 ± 4.8978 | -1.717 ± 3.9049 | -0.387 ± 4.2802 | -2.650 ± 4.2813 | -0.382 ± 4.6328 | -0.272 ± 6.0198 |
| Absolute change from Baseline to Week 26 | -2.807 ± 6.0959 | -3.068 ± 5.6339 | -1.120 ± 5.4768 | -2.681 ± 6.9089 | -2.717 ± 4.8758 | -1.203 ± 4.9043 |
Forced vital capacity (FVC) is defined as the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible. The absolute change in FVC (mL) is measured from baseline up to Weeks 4, 8, 12, 16, 20, and 26.
| mL | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Absolute change from Baseline to Week 4 | -54.7 ± 153.50 | -21.2 ± 142.25 | 4.3 ± 181.75 | 39.1 ± 152.57 | 6.0 ± 107.11 | -0.30 ± 113.07 |
| Absolute change from Baseline to Week 8 | -62.7 ± 157.81 | -38.2 ± 173.96 | -36.1 ± 165.74 | -8.8 ± 180.10 | 24.7 ± 92.87 | 11.2 ± 106.11 |
| Absolute change from Baseline to Week 12 | -75.5 ± 184.02 | -27.2 ± 173.23 | -35.4 ± 176.48 | -61.6 ± 177.42 | -1.5 ± 129.64 | 0.9 ± 128.40 |
| Absolute change from Baseline to Week 16 | -88.2 ± 183.44 | -41.0 ± 184.89 | -45.8 ± 152.79 | -44.3 ± 222.44 | -22.8 ± 146.75 | -12.1 ± 140.79 |
| Absolute change from Baseline to Week 20 | -95.6 ± 181.41 | -70.0 ± 142.70 | -21.1 ± 154.05 | -84.6 ± 134.01 | -15.2 ± 168.21 | -3.9 ± 222.29 |
| Absolute change from Baseline to Week 26 | -106.4 ± 214.94 | -117.3 ± 207.60 | -48.8 ± 184.97 | -99.1 ± 212.04 | -100.0 ± 166.30 | -37.7 ± 179.38 |
The absolute change in single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.
| mL/min/mmHg | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB) | -0.4664 (-17.023 to 5.725) | -0.3418 (-14.024 to 3.190) | -0.4518 (-5.449 to 3.888) | -0.2352 (-15.031 to 9.564) | -0.3269 (-8.902 to 2.086) | -0.1829 (-12.766 to 7.063) |
The absolute change in percent predicted single breath diffusing capacity of carbon monoxide (DLCO SB) (mL/min/mmHg) (corrected for hemoglobin) from baseline to Week 26. DLCO is defined as a measurement of the extent to which oxygen passes from the alveoli into the blood. Baseline is defined as first dose.
| Percentage of predicted value | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB) | -1.4634 (-38.133 to 64.451) | -0.3470 (-26.548 to 51.300) | -3.2455 (-48.939 to 35.463) | -1.000 (-22.176 to 11.587) | -1.4683 (-62.971 to 13.767) | -1.4609 (-13.016 to 20.997) |
The absolute change in walking endurance/distance as determined by the 6-minute walk test (6MWT) from baseline to Week 26. The 6-Minute Walk Test (6MWT) is a submaximal exercise test used to assess aerobic capacity and endurance. Baseline is defined as first dose.
| Meters | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Absolute Change From Baseline in Walking Endurance/Distance | 0.0 (-495 to 119) | 3.0 (-260 to 138) | 6.0 (-370 to 92) | 11.0000 (-315.833 to 175.000) | 0.0000 (-220.000 to 188.400) | -14.0000 (-173.000 to 242.857) |
Time to first acute exacerbations of lung fibrosis was measured from the day of first dose up to the day of first acute exacerbation. Participants who discontinued the study treatment prior to the end of the main study without experiencing the event were excluded from the analysis. A participant's time was censored at the last observed time prior to discontinuation if a participant discontinued study without event, or at week 26 if a participant did not experience the event until the end of week 26. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload
| Weeks | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| Time to First Acute Exacerbation | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | — | NA (NA to NA) |
The number of participants experiencing acute exacerbations of lung fibrosis. Acute exacerbations were defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality, as follows: 1. Acute worsening or development of dyspnea (\< 1 month duration) 2. Imaging with new bilateral ground-glass opacity and/or consolidation superimposed on a background pattern consistent with usual interstitial pneumonia 3. Respiratory deterioration not fully explained by cardiac failure or fluid overload
| Participants | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 |
|---|---|---|---|---|---|---|
| The Number of Participants Experiencing Acute Exacerbation | 2 | 3 | 1 | 3 | 0 | 1 |
Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 58 weeks). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 58 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPF Cohort - Main Study - Placebo | 4/92 (4.3%) | 16/92 (17.4%) | 57/92 (62%) |
| IPF Cohort - Main Study - 30 mg BMS-986278 | 4/91 (4.4%) | 10/91 (11%) | 54/91 (59.3%) |
| IPF Cohort - Main Study - BMS-986278 60mg | 5/93 (5.4%) | 10/93 (10.8%) | 51/93 (54.8%) |
| IPF Cohort - BMS-986278 10mg | 3/11 (27.3%) | 4/11 (36.4%) | 8/11 (72.7%) |
| IPF Cohort - OTE Phase - PBO BMS-986278 30 mg | 4/100 (4%) | 19/100 (19%) | 40/100 (40%) |
| IPF Cohort - OTE Phase - PBO BMS-986278 60mg | 6/102 (5.9%) | 23/102 (22.5%) | 43/102 (42.2%) |
| PF-ILD Cohort - Main Study - Placebo | 4/41 (9.8%) | 13/41 (31.7%) | 19/41 (46.3%) |
| PF-ILD Cohort - Main Study - BMS-986278 30mg | 0/40 (0%) | 4/40 (10%) | 23/40 (57.5%) |
| PF-ILD Cohort - Main Study - BMS-986278 60mg | 0/42 (0%) | 6/42 (14.3%) | 24/42 (57.1%) |
| PF-ILD Cohort - OTE Phase - BMS-986278 10mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| PF-ILD Cohort - OTE Phase - PBO BMS-986278 30mg | 1/41 (2.4%) | 8/41 (19.5%) | 18/41 (43.9%) |
| PF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg | 3/46 (6.5%) | 7/46 (15.2%) | 23/46 (50%) |
| Event | IPF Cohort - Main Study - Placebo | IPF Cohort - Main Study - 30 mg BMS-986278 | IPF Cohort - Main Study - BMS-986278 60mg | IPF Cohort - BMS-986278 10mg | IPF Cohort - OTE Phase - PBO BMS-986278 30 mg | IPF Cohort - OTE Phase - PBO BMS-986278 60mg | PF-ILD Cohort - Main Study - Placebo | PF-ILD Cohort - Main Study - BMS-986278 30mg | PF-ILD Cohort - Main Study - BMS-986278 60mg | PF-ILD Cohort - OTE Phase - BMS-986278 10mg | PF-ILD Cohort - OTE Phase - PBO BMS-986278 30mg | PF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 0/92 | 0/91 | 0/93 | 1/11 | 0/100 | 1/102 | 0/41 | 0/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| Forced vital capacity decreasedInvestigations | 0/92 | 0/91 | 0/93 | 1/11 | 0/100 | 0/102 | 0/41 | 0/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/92 | 0/91 | 0/93 | 1/11 | 1/100 | 0/102 | 0/41 | 0/40 | 0/42 | 0/4 | 0/41 | 1/46 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 3/92 | 4/91 | 0/93 | 1/11 | 8/100 | 7/102 | 1/41 | 0/40 | 0/42 | 0/4 | 1/41 | 0/46 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/92 | 1/91 | 0/93 | 0/11 | 0/100 | 0/102 | 2/41 | 0/40 | 1/42 | 0/4 | 1/41 | 0/46 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/92 | 0/91 | 0/93 | 0/11 | 0/100 | 3/102 | 0/41 | 0/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| COVID-19Infections and infestations | 0/92 | 0/91 | 0/93 | 0/11 | 1/100 | 1/102 | 0/41 | 1/40 | 0/42 | 0/4 | 1/41 | 0/46 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/92 | 0/91 | 0/93 | 0/11 | 0/100 | 0/102 | 0/41 | 1/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| Pneumonia legionellaInfections and infestations | 0/92 | 0/91 | 0/93 | 0/11 | 0/100 | 0/102 | 0/41 | 1/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| Femur fractureInjury, poisoning and procedural complications | 0/92 | 0/91 | 0/93 | 0/11 | 0/100 | 0/102 | 0/41 | 1/40 | 0/42 | 0/4 | 0/41 | 0/46 |
| Event | IPF Cohort - Main Study - Placebo | IPF Cohort - Main Study - 30 mg BMS-986278 | IPF Cohort - Main Study - BMS-986278 60mg | IPF Cohort - BMS-986278 10mg | IPF Cohort - OTE Phase - PBO BMS-986278 30 mg | IPF Cohort - OTE Phase - PBO BMS-986278 60mg | PF-ILD Cohort - Main Study - Placebo | PF-ILD Cohort - Main Study - BMS-986278 30mg | PF-ILD Cohort - Main Study - BMS-986278 60mg | PF-ILD Cohort - OTE Phase - BMS-986278 10mg | PF-ILD Cohort - OTE Phase - PBO BMS-986278 30mg | PF-ILD Cohort - OTE Phase - PBO BMS-986278 60mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dental cariesGastrointestinal disorders | 0/92 | 0/91 | 1/93 | 1/11 | 0/100 | 0/102 | 0/41 | 0/40 | 0/42 | 1/4 | 0/41 | 1/46 |
| FatigueGeneral disorders | 4/92 | 5/91 | 1/93 | 0/11 | 2/100 | 4/102 | 1/41 | 0/40 | 3/42 | 1/4 | 1/41 | 1/46 |
| BronchitisInfections and infestations | 1/92 | 4/91 | 1/93 | 1/11 | 4/100 | 5/102 | 2/41 | 1/40 | 0/42 | 1/4 | 2/41 | 3/46 |
| COVID-19Infections and infestations | 7/92 | 3/91 | 9/93 | 1/11 | 12/100 | 8/102 | 2/41 | 5/40 | 6/42 | 1/4 | 7/41 | 6/46 |
| InfluenzaInfections and infestations | 0/92 | 0/91 | 1/93 | 0/11 | 0/100 | 0/102 | 0/41 | 1/40 | 0/42 | 1/4 | 0/41 | 1/46 |
| Upper respiratory tract infectionInfections and infestations | 1/92 | 3/91 | 1/93 | 0/11 | 1/100 | 3/102 | 1/41 | 0/40 | 3/42 | 1/4 | 1/41 | 1/46 |
| Blood bilirubin increasedInvestigations | 0/92 | 0/91 | 0/93 | 0/11 | 0/100 | 0/102 | 0/41 | 1/40 | 0/42 | 1/4 | 1/41 | 0/46 |
| Decreased appetiteMetabolism and nutrition disorders | 1/92 | 1/91 | 4/93 | 0/11 | 1/100 | 0/102 | 0/41 | 1/40 | 0/42 | 1/4 | 0/41 | 0/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/92 | 4/91 | 4/93 | 0/11 | 3/100 | 0/102 | 1/41 | 0/40 | 2/42 | 1/4 | 1/41 | 2/46 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/92 | 0/91 | 0/93 | 0/11 | 1/100 | 0/102 | 0/41 | 0/40 | 0/42 | 1/4 | 0/41 | 0/46 |
The baseline characteristics are reported for the safety population which is all treated participants.
| Age, Continuous(Years) | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | Total |
|---|---|---|---|---|---|---|---|
| Mean | 69.0 ± 6.70 | 69.5 ± 7.31 | 68.8 ± 7.85 | 68.8 ± 8.06 | 71.4 ± 7.92 | 67.9 ± 8.41 | 69.5 ± 8.22 |
| Sex: Female, Male(Participants) | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | Total |
|---|---|---|---|---|---|---|---|
| Female | 16 | 14 | 24 | 21 | 17 | 20 | 112 |
| Male | 76 | 77 | 69 | 20 | 23 | 22 | 287 |
| Ethnicity (NIH/OMB)(Participants) | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 18 | 19 | 7 | 6 | 9 | 80 |
| Not Hispanic or Latino | 39 | 36 | 37 | 19 | 21 | 22 | 174 |
| Unknown or Not Reported | 32 | 37 | 37 | 15 | 13 | 11 | 145 |
| Race (NIH/OMB)(Participants) | IPF Cohort: Placebo | IPF Cohort: 30 mg BMS-986278 | IPF Cohort: 60 mg BMS-986278 | PF-ILD Cohort: Placebo | PF-ILD Cohort: 30 mg BMS-986278 | PF-ILD Cohort: 60 mg BMS-986278 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Asian | 25 | 25 | 27 | 8 | 9 | 6 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 2 | 0 | 3 |
| White | 65 | 64 | 64 | 31 | 27 | 32 | 283 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 1 | 2 | 2 | 4 | 12 |
Showing the first 100 of 119 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Aug 2022, 24 months.
Results were first posted in Feb 2025, 2 years 6 months after primary completion. A results delay was requested in Jul 2023.
Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's 24 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Admilparant